China Medical Technologies Spends $345M for Rights to HPV Testing Platform | GenomeWeb
NEW YORK (GenomeWeb News) – China Medical Technologies said yesterday that it had entered into a definitive agreement to acquire a molecular diagnostic test for human papillomavirus and an analysis platform from Molecular Diagnostic Technologies for $345 million.
 
The Beijing-based firm said that it will acquire the HPV-DNA Biosensor Chip and a surface plasmon resonance-based system for detecting the virus.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.